Log in

NASDAQ:ITCIIntra-Cellular Therapies Stock Price, Forecast & News

$21.05
-0.97 (-4.41 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$20.87
Now: $21.05
$22.45
50-Day Range
$15.29
MA: $19.05
$23.66
52-Week Range
$6.75
Now: $21.05
$43.56
Volume722,133 shs
Average Volume1.16 million shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.85
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Read More
Intra-Cellular Therapies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.54 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ITCI
CUSIPN/A
Phone646-440-9333

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$60,000.00
Price / Sales23,313.23
Book Value$6.48 per share

Profitability

Net Income$-147,720,000.00

Miscellaneous

Employees73
Market Cap$1.40 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive ITCI News and Ratings via Email

Sign-up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.

Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions

How has Intra-Cellular Therapies' stock been impacted by COVID-19 (Coronavirus)?

Intra-Cellular Therapies' stock was trading at $17.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ITCI shares have increased by 18.5% and is now trading at $21.05. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Intra-Cellular Therapies?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Intra-Cellular Therapies.

When is Intra-Cellular Therapies' next earnings date?

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Intra-Cellular Therapies.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies Inc (NASDAQ:ITCI) released its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.93) by $0.20. The biopharmaceutical company earned $1.08 million during the quarter, compared to the consensus estimate of $1.75 million. View Intra-Cellular Therapies' earnings history.

What price target have analysts set for ITCI?

10 Wall Street analysts have issued twelve-month target prices for Intra-Cellular Therapies' shares. Their forecasts range from $16.00 to $68.00. On average, they anticipate Intra-Cellular Therapies' stock price to reach $37.13 in the next twelve months. This suggests a possible upside of 76.4% from the stock's current price. View analysts' price targets for Intra-Cellular Therapies.

Has Intra-Cellular Therapies been receiving favorable news coverage?

Media headlines about ITCI stock have trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Intra-Cellular Therapies earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutIntra-Cellular Therapies.

Who are some of Intra-Cellular Therapies' key competitors?

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Amarin (AMRN), Crispr Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Gilead Sciences (GILD), AbbVie (ABBV), Clovis Oncology (CLVS), Novavax (NVAX), Myovant Sciences (MYOV), ACADIA Pharmaceuticals (ACAD) and Karyopharm Therapeutics (KPTI).

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the following people:
  • Dr. Sharon Mates, Co-Founder, Chairman, CEO & Pres (Age 66)
  • Mr. Lawrence J. Hineline CPA, Sr. VP of Fin., CFO, Treasurer and Assistant Sec. (Age 63)
  • Dr. Robert E. Davis, Sr. VP & Chief Scientific Officer (Age 68)
  • Mr. Michael I. Halstead J.D., Exec. VP, Gen. Counsel, Corp. Compliance Officer & Sec. (Age 46)
  • Dr. Andrew Satlin M.D., Exec. VP & Chief Medical Officer (Age 64)

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.70%), Wasatch Advisors Inc. (4.43%), State Street Corp (1.86%), Samlyn Capital LLC (1.74%), Schroder Investment Management Group (1.68%) and St. Louis Trust Co (1.33%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View institutional ownership trends for Intra-Cellular Therapies.

Which institutional investors are selling Intra-Cellular Therapies stock?

ITCI stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, JPMorgan Chase & Co., Voloridge Investment Management LLC, General American Investors Co. Inc., DCF Advisers LLC, CSS LLC IL, and UBS Group AG. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, and Sharon Mates. View insider buying and selling activity for Intra-Cellular Therapies.

Which institutional investors are buying Intra-Cellular Therapies stock?

ITCI stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Ikarian Capital LLC, Samlyn Capital LLC, St. Louis Trust Co, BlackRock Inc., Alyeska Investment Group L.P., Schroder Investment Management Group, and Invesco Ltd.. View insider buying and selling activity for Intra-Cellular Therapies.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $21.05.

How big of a company is Intra-Cellular Therapies?

Intra-Cellular Therapies has a market capitalization of $1.40 billion and generates $60,000.00 in revenue each year. The biopharmaceutical company earns $-147,720,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.

What is Intra-Cellular Therapies' official website?

The official website for Intra-Cellular Therapies is www.intracellulartherapies.com.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.